Objectives This study sought to predict the value of tumor marker carbohydrate antigen 125 (CA125) before and after transcatheter aortic valve implantation (TAVI) for all-cause death and a composite endpoint of death, admission for heart failure, myocardial infarction, and stroke (major adverse cardiac events [MACE]).
Transcatheter aortic valve implantation (TAVI) is increasingly used as a therapeutic option for patients with symptomatic aortic stenosis and elevated surgical risk. It has been shown to be superior to medical therapy in patients with prohibitive elevated risk (1) while being comparable to conventional surgical aortic valve replacement in high-risk patients (2) .
Due to a high comorbid burden present in this population, the prediction of outcome after TAVI is very challenging. In this population, identifying the intrinsic role of the procedure on outcomes must be dissected from the effect of the associated comorbidities, progression of comorbid conditions and elevated age. Potentially, biomarkers may play an important role in this setting. The first studies on the prognostic usefulness of biomarkers in TAVI have relied on natriuretic peptides. However, these studies were conducted in a small series of patients and yielded conflicting results (3) (4) (5) .
Tumor marker carbohydrate antigen 125 (CA125) is an emerging cardiac biomarker. In heart failure (HF), CA125 has shown to be elevated and is released by mesothelial cells as a response to serosal effusions and inflammation (6, 7) . It has been shown that CA125 is strongly related to HF severity and adverse outcomes in HF (8 -10) . Recently, in the setting of aortic stenosis, elevated levels of CA125 have also shown to be associated with disease severity and adverse outcomes (11) . To date, however, there are no data on the prognostic value of CA125 after TAVI. We hypothesized that CA125, as a baseline measurement, might be a useful prognostic biomarker in patients undergoing TAVI. Additionally, and more importantly, we hypothesized that changes in CA125 after TAVI might be strongly indicative of adverse outcomes following TAVI. As such, the aim of this study was 2-fold: 1) to evaluate the prognostic significance of pre-procedural values of CA125; and 2) to determine whether repeated measurements of CA125 after TAVI remain indicative of elevated risk.
Methods

Patients and indications.
We included 228 consecutive patients undergoing TAVI in our institution. TAVI was performed due to degenerative calcified native aortic stenosis in 211 cases (93%), degenerated bioprostheses in 13 cases (6%), and severe aortic regurgitation in 4 cases (2%). An interdisciplinary heart team discussed all cases, and consensus was reached regarding the best therapeutic strategy in each individual case. The local ethics committee approved the study protocol, and all patients provided written informed consent to participate in a clinical registry. Description of the TAVI procedures. TAVI was performed either via the transfemoral approach (n ϭ 137) using a balloon expandable (SAPIEN XT, Edwards Lifesciences, Irvine, California, n ϭ 79) or a self-expandable prosthesis (CoreValve, Medtronic, Irvine, California, n ϭ 58) or by the transapical approach (n ϭ 89) using a balloon expandable prosthesis (SAPIEN XT, Edwards Lifesciences). In 2 cases, a different access route was used (subclavian and direct aortic). Access route was dichotomized as "transfemoral" versus "non-transfemoral." TAVI procedures were performed in the catheterization laboratory or the hybrid operating suite under general anesthesia. TAVI operators were unaware of CA125 values. Laboratory analyses and CA125 measurement. CA125 was determined from routine blood samples using a chemiluminometric immunoassay (ADVIA Centaur, Siemens Healthcare, Erlangen, Germany) at least 24 h before TAVI and on follow-up visits. Blood samples were measured and analyzed immediately. The manufacturer's cutoff value for a pathological test result is Ͼ30 U/ml. Follow-up and definition of outcomes. All data were prospectively collected. Two cardiologists and 3 trained nurses, unaware of CA125 values, were in charge of patients' follow-up. Scheduled visits took place on a 3-month basis during outpatients' clinic visits, telephone interviews with the patient or his/her family, or by reviewing the patient's hospital record. Patients were scheduled at the outpatient clinic (at least 1 to 3 and 6 to 12 months after TAVI) for clinical and echocardiographic examinations as well as blood sampling.
The endpoints of this study were all-cause death and major adverse cardiac events (MACE) defined as a composite of all-cause death, acute HF requiring admission, myocardial infarction, and stroke, whichever occurred first during follow-up. Procedure-related death, but not other procedural complications, were included into MACE. To adjudicate an event, consensus between the 2 cardiologists was required.
Thirty-day mortality was defined as death from any cause during the first 30 days after the procedure or as intrahospital death after the TAVI procedure. Procedural success was defined using the following criteria: successful vascular access, delivery, and deployment of the device with successful retrieval of the delivery system, correct position of the device in the proper anatomical location with adequate performance, and the patient leaving the operating theater alive. Device success and procedural complications were categorized using criteria defined by the Valve Academic Research Consortium (12) . In short, device success was defined as procedural success with a correct position and function of the prosthesis (less than grade 2 residual aortic regurgitation) and only 1 valve implanted per patient (12) . Statistical analysis. Continuous variables were expressed as a mean Ϯ SD or as the median (interquartile range) and using the unpaired Student t test or Mann-Whitney U test as appropriate. Discrete variables were compared with the chi-square test or Fisher exact test as appropriate. Outcome rates were depicted among the populations according to the median and manufacturer's cutoff value (30 U/ml) of CA125 using the Kaplan-Meier method and compared with the log-rank test. BASELINE ANALYSIS. A multivariable time-to-event analysis was performed using a flexible parametric survival analysis (13) . For this analysis, our primary exposure was CA125 continuous (transformed by its logarithm, lnCA125); however, we also tested for the prognostic effect of CA125, either dichotomized according to the median (M2 vs. M1) or according to the manufacturer's cutoff value (30 U/ml). Baseline covariates were chosen based on scientific knowledge, regardless of their p value in the univariate analysis. The final baseline model included logistic EuroSCORE, New York Heart Association (NYHA) functional class III/IV, and device success as covariates. The model's discrimination and calibration was assessed by the Harrell's C statistic and the Hosmer-Lemeshow test, respectively. LONGITUDINAL ANALYSIS. In order to test whether longitudinal measures of CA125 better discriminate those patients with a higher likelihood of adverse outcomes, CA125 levels (and other relevant prognostic factors) were collected before TAVI (baseline) and every 3 months afterward until last time point of event-free follow-up or the date of death (or MACE). Apart from CA125, those prognostic factors that were missing during follow-up, and thus could not be used as time-varying variables, were included in the models using the respective baseline values. To account for the fact that our study includes a repeated-measures design with a survival endpoint, we used a Joint Modeling (JM) approach. This is a family of methods that has been developed to explicitly account for the dependence between the longitudinal change of a continuous exposure and event time data (14) . The benefits of the joint modeling approach compared with the traditional Cox regression models is the fact that it accounts for the measurement error (i.e., biological variation) and the informative dropout in CA125, and that it can give more efficient results (i.e., smaller standard errors) by combining information from the longitudinal and survival outcomes (15) . Joint models of this type combine a linear mixed effect that describes the longitudinal trajectory of a continuous exposure, with a proportional hazards model for the time-to-event. In the former model, covariates and random terms (random intercepts and random slopes) are selected using a likelihood-ratio test. In the latter model, the fitted exposure trajectory is related to the hazard for event through a parametric Cox analysis.
In order to determine how longitudinally updated values of CA125 relate with the hazard for death or MACE, we modeled its natural logarithm within a linear mixed regression framework that include random intercept and slopes (heretofore called the longitudinal submodel). N-terminal pro-B-type natriuretic peptide (NT-proBNP) (transformed by its natural logarithm) was added as a time-varying covariate. Time (in weeks) was included as a random effect and modeled with a polynomial of power Ϫ1. Sex, logistic EuroSCORE of 20%, and left ventricular ejection fraction (%) were included as time-constant covariates (with their respective baseline values).
In the survival approach (heretofore called the survival submodel), the predicted time-history of lnCA125 from the linear mixed model was related to the hazard for death or MACE through a time-varying parametric Cox. Here, the hazard function was modeled with restricted cubic splines. The final model included lnNT-proBNP as a time-varying covariate, whereas the logistic EuroSCORE, device success and NYHA functional class III/IV were included as timeconstant covariates.
The survival estimates are presented as hazard ratios (HR) with the 95% confidence intervals (CI).
A 2-sided p value of Ͻ0.05 was considered statistically significant for all analyses. Baseline analyses were carriedout using Stata (StataCorp, Stata Statistical Software Release 12, College Station, Texas). The longitudinal analyses were performed with the statistical module JM (16) in R (R Foundation for Statistical Computing, Vienna, Austria).
Results
The baseline clinical, echocardiographic, and laboratory characteristics of the entire study population are displayed in Table 1 . TAVI was successfully performed in 221 patients (97%) with device success achieved in 196 cases (86%). Procedural mortality was 2% (5 of 228), and the overall 30-day mortality was 7% (15 of 228). The procedural data and complications are depicted in Table 2 . Table 1 . Baseline CA125 and adverse outcome after TAVI. The clinical, laboratory, echocardiographic and procedural characteristics of the patients at baseline were stratified according to the median of CA125, and are presented in Tables 3 and 4 . Median pre-procedural CA125 was higher in patients who died (28 U/ml [15 to 51] vs. 12 U/ml [8 to 29] ; p ϭ 0.001) and who experienced MACE (23 U/ml [9 to 28] vs. 14 U/ml [9 to 28]; p ϭ 0.003).
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Husser et al. CA125 in TAVI An approximate 3-fold increase in the rate of death and MACE was observed in patients with elevated baseline CA125 (M2 ϭ 5.2 vs. M1 ϭ 1.6 per 10 persons-year and M2 ϭ 8.3 vs. M1 ϭ 3.3, respectively; p for both Ͻ0.001) and for CA125 Ͼ30 U/ml versus CA125 Յ30: 6.1 versus 2.3 per 10 persons-year and 9.5 versus 4.2 per 10 personsyear, respectively; p for both Ͻ0.001). These differences were consistent along the entire follow-up. Using the Kaplan-Meier method, the cumulative event rates for allcause death and MACE are displayed in Figures 1 and 2 and in Online Figures 1 and 2 .
In the multivariate analysis, after adjusting for the logistic EuroSCORE, NYHA functional class III/IV and device success, baseline CA125 (M2 vs. M1) remained independently associated with an increased risk of all-cause death (HR: 2.18; 95% CI: 1.11 to 4.26; p ϭ 0.023) and MACE Values are mean Ϯ SD, n (%), or median [interquartile range]. *Severely affecting ambulation or day-to-day functioning. †Serum creatinine Ͼ200 mol/l. ‡On long-term use of bronchodilators or steroids. §Pulmonary artery pressure Ն60 mm Hg.
CABG ϭ coronary artery bypass graft; CAD ϭ coronary artery disease; COPD ϭ chronic obstructive pulmonary disease; LVEF ϭ left ventricular ejection fraction; MACE ϭ major adverse cardiac events; MI ϭ myocardial infarction; NT-proBNP ϭ N-terminal pro-B-type natriuretic peptide; NYHA ϭ New York Heart Association; PAH ϭ pulmonary arterial hypertension; PCI ϭ percutaneous coronary intervention; SAVR ϭ surgical aortic valve replacement; TF ϭ transfemoral. (HR: 1.77; 95% CI: 1.05 to 2.98; p ϭ 0.031). Risk estimates were borderline significant for CA125 Ͼ30 U/ml, and nonsignificant for lnCA125 (Table 5 ). The Harrell's C statistics of the multivariate models with and without CA125 (Ͼmedian) were 0.724 versus 0.697 for all-cause death and 0.695 versus 0.678 for MACE. In a sensitivity analysis, in which NT-proBNP (either as a continuous variable or dichotomized by its median) was forced into the final model, it was not associated with either endpoint (Table 5 ). In such analyses, however, the association of CA125 (M2 vs. M1) with the risk of all-cause death (HR: 2.20; 95% CI: 1.11 to 4.34; p ϭ 0.023) and MACE (HR: 1.78; 95% CI: 1.05 to 3.01; p ϭ 0.031) remained almost unaltered. Table 6 .
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The output from the JM-survival submodel identified lnCA125 as a powerful and independent predictor of both endpoints (Table 6 ). After controlling for lnNT-proBNP (modeled as a time-varying covariate), and baseline values of the logistic EuroSCORE, NYHA functional class III/IV, and device success, we found that for each unit increase in lnCA125, there was a predicted 47% increase for the risk of death. For MACE, the predicted increase of risk was even greater (more than 2-fold) (see Table 6 for the estimates). Of note, the regression estimate for lnCA125 did not change significantly after eliminating the nonsignificant variables from the model (EuroSCORE and lnNT-proBNP).
Two additional sensitivity analyses were performed to evaluate the prognostic significance of CA125 (M2 vs. M1) and CA125 (Ͼ30 vs. Յ30 U/dl). Here, lnNT-proBNP was modeled as a time-varying exposure instead of lnCA125. In the first analysis, CA125 (M2 vs. M1), but not lnNTproBNP, was independently related to the risk of death (HR: Table 2 ). In both analyses, lnNT-proBNP, either as a main time-varying exposure or as a time-varying covariate, was not significantly associated with either endpoint.
Discussion
The present study is the first, to our knowledge, to assess the prognostic value of CA125 in TAVI. It could be shown that first, CA125 (modeled as lnCA125) was a strong predictor of death or MACE in a longitudinal setting. Explicitly, using JM analysis, serial CA125 measurements after TAVI were significant predictors of both outcomes, even when modeled simultaneously with time-varying NT-proBNP, logistic EuroSCORE, baseline NYHA functional class III/IV, and device success. Second, patients with elevated baseline CA125 values (above the median) showed an independent increase of risk for all-cause death or MACE after TAVI. Risk prediction in TAVI. Risk prediction in TAVI is an important research avenue aimed at the identification of those patients who might benefit most from close follow-up and/or additional monitoring after the procedure. However, this is a challenging goal, mainly because despite successful TAVI, patients still remain at high risk for adverse events due to an extremely high burden of comorbidity. This issue becomes evident by a relative high mortality rate during follow-up as has been reported from randomized trials (17) and registries (18) CA125-M1 ϭ below the median; CA125-M2 ϭ above the median; other abbreviations as in Table 1 . Abbreviations as in Tables 1 and 2 . with a comparable rate of procedural and device success as in the present study. Thus, in TAVI, there is an unmet need to discover novel tools to improve the prediction of outcomes and to discriminate those patients who may benefit the most. In this way, risk prediction using pre-procedural variables is the most appealing approach, since it bears the potential to determinate expected benefit from the procedure and therefore to allow a more rational treatment allocation. Several scores, such as the logistic EuroSCORE (19) or the STS score (20) , have been proposed to summarize all prognostic factors. Biomarkers, in this setting, might be envisioned, not only as a tool for pre-procedural risk assessment, but also for monitoring treatment success after TAVI. Biomarkers in TAVI. Natriuretic peptides show elevated values in aortic stenosis, correlate with disease severity, and have been used to predict symptom-free survival, prognosis, and post-operative outcome (21) (22) (23) . As a consequence, these biomarkers were the first to be studied for risk prediction in the setting of TAVI (3) (4) (5) . Nevertheless, these studies have been conducted in small populations and short-term follow-up, and have yielded conflicting results.
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In our study, although lnNT-proBNP was associated with death and MACE, we did not find a prognostic value of NT-proBNP when modeled concomitantly with CA125 and other adjusting covariates. This was true for baseline values as well as in the JM analyses. These negative findings may be explained by the fact that NT-proBNP has a short half-life (24) and is therefore of limited use to assess long-term prognosis. Additionally, the high prevalence of old age and renal dysfunction in this population may also explain the limited use of this biomarker in this setting. Finally, a high correlation found between NT-proBNP and CA125 (r ϭ 0.49) in the present study may also play a role.
Additionally, periprocedural elevations of cardiac necrosis markers (e.g., troponin or creatine kinase-myocardial band) have been associated with an increased mortality and a lesser degree of improvement of left ventricular ejection fraction (25) . Because we did not perform routine troponin determination in our present study population, we cannot provide a comparison of CA125. Emerging evidence, however, allows us to speculate that most patients who meet the criteria for TAVI will have pre-procedural troponin determinations within normal limits. Clinical role of CA125 following TAVI. CA125 is an emerging biomarker in HF and is released by mesothelial cells in response to the presence of serosal effusions and/or proin- To the left, the cumulative rate of major adverse cardiac events (MACE) is depicted with Kaplan-Meier method, whereas on the right, the crude MACE rates are shown. TAVI ϭ transcatheter aortic valve implantation. To the left, the cumulative rate of all-cause death is depicted with Kaplan-Meier method, whereas on the right, the crude death rates are shown. TAVI ϭ transcatheter aortic valve implantation. flammatory cytokines (6) . These 2 triggers of CA125 are pathophysiological mechanisms, which are profoundly related to the severity and progression of HF (26 -28) . Accordingly, previous studies have shown that CA125 is associated with disease severity and outcome in HF (8 -10,29,30) . Moreover, a recent study has shown that CA125 is also elevated in symptomatic severe aortic stenosis and correlates with symptom severity and outcomes (11) .
In the present study, elevated CA125 levels before TAVI and during follow-up were associated with a higher rate of death and MACE. These effects were independent of established risk predictors, such as the logistic Euro-SCORE, NYHA functional class III/IV, or device success. When compared with NT-proBNP, CA125 showed a clear superiority as a prognostic biomarker, perhaps due to its stability and longer half-life (around 7 to 12 days) (31) . Subject-specific longitudinal trajectories of LnCA125 for patients who were censored or reached an endpoint. Solid lines denote the fit of the loess smoother. Time scale is adjusted to each patient's survival time. A and B display the longitudinal trajectories across died/censoring or MACE/censoring status, respectively. In patients who were censored and did not reach an endpoint (censored ϭ last contact alive and event-free), CA125 levels remain relatively stable with a slight decreasing tendency over time. By contrast, patients who experienced an event, lnCA125 levels show an elevation as they get closer to the event. MACE ϭ major adverse cardiac events. Additionally, as a biomarker, CA125 possesses some more theoretical advantages. First, levels of this biomarker show a close relationship with HF severity and increased risk of death and subsequent readmission for acute HF (8 -10,28) . Second, it is widely available and less expensive than other biomarkers. Third, plasma levels do not seem to be relevantly influenced by age, renal function, or body mass index (8, 9) . Fourth, evidence from data in patients with acute HF supports the hypothesis that changes in CA125 over time are more likely due to changes in disease status than to biological variation (9, 29) . Moreover, with a half-life longer than 1 week, CA125 does not seem to be a marker with high short-term variability. These properties advocate CA125 as the ideal biomarker to monitor the evolution of our elderly TAVI patients. Despite being a stable biomarker, CA125 has shown temporal trajectories that closely follow the functional status of the patient, and consequently, discriminates those patients at high risk for adverse outcomes (29) . Clinical implications. First, baseline CA125 values might be a useful tool for the determination of the optimal time point for TAVI. Those patients with elevated levels of CA125 may require a more aggressive treatment before the procedure. Perhaps the subgroup with persistently elevated levels of CA125 may not benefit at all from the procedure.
Second, our longitudinal results support the potential for the use of this biomarker for monitoring the clinical evolution after TAVI. Potentially, patients with rising levels of CA125 after TAVI may be regarded to be at high risk for events and consequently may require close clinical observation and/or intensified treatment. At this moment, however, it is unclear whether normalization of CA125 values by a more aggressive treatment before and/or after TAVI, will attenuate the elevated risk for adverse events. The answer to this question will require additional studies and, more importantly, clinical trials specifically designed to address this issue. Strength and limitations. First, this is the first to evaluate the prognostic usefulness of CA125 in a novel setting (patients undergoing TAVI). Second, a novel statistical approach for modeling repeated measurements of CA125 is employed. This allowed us to monitor the follow-up of the patients after TAVI with more statistical precision than using baseline values of the biomarker alone.
An inherent limitation of the JM analysis, we were not able to explore a more flexible functional form of CA125. However, our previous experience with CA125 in acute HF supports the use of either linear or logarithmic transformation when related to the log hazard for all-cause mortality. Finally, some variables were missing during follow-up and were included in the longitudinal models with their baseline values.
Conclusions
This study demonstrated for the first time that CA125 is an excellent prognostic tool for monitoring the evolution of EuroSCORE ϭ the logistic EuroSCORE continuous; EuroSCORE20 ϭ the logistic EuroSCORE dichotomized(Ͼ20%); lnCA125 ϭ natural logarithm of CA125; lnNT-proBNP ϭ natural logarithm of NT-proBNP; other abbreviations as in Tables 1 and 5 . CA125 in TAVI patients undergoing TAVI. Elevated pre-procedural and the longitudinal evolution of CA125 levels predicted adverse outcomes after TAVI.
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